Dimension Therapeutics Announces Presentations Highlighting Advances in AAV Manufacturing at the European Society of Gene and Cell ...
CAMBRIDGE, Mass., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced …